BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35486183)

  • 1. Expression and clinical prognostic value of CYB561 in breast cancer.
    Zhou X; Shen G; Ren D; Guo X; Han J; Guo Q; Zhao F; Wang M; Dong Q; Li Z; Zhao J
    J Cancer Res Clin Oncol; 2022 Aug; 148(8):1879-1892. PubMed ID: 35486183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cytochrome b561 Serves as a Potential Prognostic Biomarker and Target for Breast Cancer.
    Yang X; Zhao Y; Shao Q; Jiang G
    Int J Gen Med; 2021; 14():10447-10464. PubMed ID: 35002301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Integrated analysis identifies TfR1 as a prognostic biomarker which correlates with immune infiltration in breast cancer.
    Chen F; Fan Y; Hou J; Liu B; Zhang B; Shang Y; Chang Y; Cao P; Tan K
    Aging (Albany NY); 2021 Sep; 13(17):21671-21699. PubMed ID: 34518441
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estrogen receptor 1 and progesterone receptor are distinct biomarkers and prognostic factors in estrogen receptor-positive breast cancer: Evidence from a bioinformatic analysis.
    Wu JR; Zhao Y; Zhou XP; Qin X
    Biomed Pharmacother; 2020 Jan; 121():109647. PubMed ID: 31733575
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SOX13 is a novel prognostic biomarker and associates with immune infiltration in breast cancer.
    Gao T; Jiang B; Zhou Y; He R; Xie L; Li Y
    Front Immunol; 2024; 15():1369892. PubMed ID: 38707897
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytochrome b561 regulates iron metabolism by activating the Akt/mTOR pathway to promote Breast Cancer Cells proliferation.
    Zhou X; Guo X; Han J; Wang M; Liu Z; Ren D; Zhao J; Li Z
    Exp Cell Res; 2023 Oct; 431(1):113760. PubMed ID: 37634562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
    Heimes AS; Madjar K; Edlund K; Battista MJ; Almstedt K; Gebhard S; Foersch S; Rahnenführer J; Brenner W; Hasenburg A; Hengstler JG; Schmidt M
    J Cancer Res Clin Oncol; 2017 Jul; 143(7):1123-1131. PubMed ID: 28251349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of DRP1 as a prognostic factor correlated with immune infiltration in breast cancer.
    Liu B; Fan Y; Song Z; Han B; Meng Y; Cao P; Tan K
    Int Immunopharmacol; 2020 Dec; 89(Pt B):107078. PubMed ID: 33049497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of the prognostic value and immune function of chemokine-CXC receptor family members in breast cancer.
    Lyu L; Zheng Y; Hong Y; Wang M; Deng Y; Wu Y; Xu P; Yang S; Wang S; Yao J; Zhang D; Guo Y; Lyu J; Dai Z
    Int Immunopharmacol; 2020 Oct; 87():106797. PubMed ID: 32702599
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic and immunological value of
    Wang J; Liu Y; Zhang S
    Aging (Albany NY); 2021 Jul; 13(13):16904-16921. PubMed ID: 34228637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced Expression of KRT17 Predicts Poor Prognosis in HER2
    Tang S; Liu W; Yong L; Liu D; Lin X; Huang Y; Wang H; Cai F
    Biomolecules; 2022 Aug; 12(9):. PubMed ID: 36139022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NEDD4 expression is associated with breast cancer progression and is predictive of a poor prognosis.
    Wan L; Liu T; Hong Z; Pan Y; Sizemore ST; Zhang J; Ma Z
    Breast Cancer Res; 2019 Dec; 21(1):148. PubMed ID: 31856858
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the role of FADS family members in breast cancer based on bioinformatic analysis and experimental validation.
    Zhao T; Gao P; Li Y; Tian H; Ma D; Sun N; Chen C; Zhang Y; Qi X
    Front Immunol; 2023; 14():1074242. PubMed ID: 37122728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LAYN Is a Prognostic Biomarker and Correlated With Immune Infiltrates in Gastric and Colon Cancers.
    Pan JH; Zhou H; Cooper L; Huang JL; Zhu SB; Zhao XX; Ding H; Pan YL; Rong L
    Front Immunol; 2019; 10():6. PubMed ID: 30761122
    [No Abstract]   [Full Text] [Related]  

  • 15. Coexpression of PBX1 and EMP2 as Prognostic Biomarkers in Estrogen Receptor-Negative Breast Cancer via Data Mining.
    Qiu Y; Lu G; Wu Y
    J Comput Biol; 2020 Oct; 27(10):1509-1518. PubMed ID: 32216630
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinicopathological Features, Tumor Mutational Burden, and Tumour-Infiltrating Lymphocyte Interplay in
    Uchida S; Kojima T; Sugino T
    Pathol Oncol Res; 2021; 27():633243. PubMed ID: 34257600
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Systematic analysis of lncRNA-miRNA-mRNA competing endogenous RNA network identifies four-lncRNA signature as a prognostic biomarker for breast cancer.
    Fan CN; Ma L; Liu N
    J Transl Med; 2018 Sep; 16(1):264. PubMed ID: 30261893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Overexpressed VDAC1 in breast cancer as a novel prognostic biomarker and correlates with immune infiltrates.
    Fang Y; Liu J; Zhang Q; She C; Zheng R; Zhang R; Chen Z; Chen C; Wu J
    World J Surg Oncol; 2022 Jun; 20(1):211. PubMed ID: 35729567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Integrative analysis of prognostic value and immune infiltration of spindle and kinetochore-associated family members in breast cancer.
    Ding J; He X; Wang J; Cao G; Chen S; Yuan L; Chen B; Xiong M
    Bioengineered; 2021 Dec; 12(2):10905-10923. PubMed ID: 34845974
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High methionyl-tRNA synthetase expression predicts poor prognosis in patients with breast cancer.
    Jin Q; Liu G; Wang B; Li S; Ni K; Wang C; Ren J; Zhang S; Dai Y
    J Clin Pathol; 2020 Dec; 73(12):803-812. PubMed ID: 32404475
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.